Over 20 scientific abstracts from AstraZeneca’s cardiovascular and metabolic disease portfolio will be presented at this year’s European Society of Cardiology (ESC) Congress 2015 in London, including five oral presentations. Data being presented will focus on the early management of Acute Coronary Syndromes (ACS) and long-term secondary prevention of atherothrombotic events in patients who have previously suffered a heart attack.
Presentation of the data, including sub-analyses of the BRILINTA® PEGASUS-TIMI 54 study, coincides with updates to the ESC guidelines on treatment of Non-ST Segment Elevation Myocardial Infarction patients, which will be presented at the congress on Sunday, 30 August. The updated guidelines will provide insight into long term dual antiplatelet therapy for patients with a history of heart attack.
The PEGASUS-TIMI 54 study sub-analyses will provide further understanding of the types of patients most likely to benefit from long-term treatment with BRILINTA. The data will also provide insight into the relationship between the time from a patient’s last treatment with P2Y12 antiplatelet therapy and their risk of a subsequent heart attack, stroke or cardiovascular death as well as the effect of BRILINTA in this setting.
Elisabeth Björk, Vice President, Head of Cardiovascular and Metabolic Diseases, Global Medicines Development, AstraZeneca, said: “It is encouraging to see guideline updates recognise the continuing risk for patients more than one year after their heart attack and consider how this risk can be managed. We are looking forward to the presentation of the PEGASUS-TIMI 54 sub-analyses during the ESC Congress 2015 and to continuing the debate about the long-term use of dual antiplatelet therapy for these patients.”
In March 2015, based on the results of the PEGASUS-TIMI 54 study1, the US Food and Drug Administration (FDA) granted Priority Review for BRILINTA for the prevention of atherothrombotic events in patients who have previously experienced a heart attack.
Additional sub-analyses of the PEGASUS-TIMI 54 study also being presented at the ESC Congress 2015 include research into the relationship between renal function and risk of ischaemic and bleeding events, evaluated in a subset of high-risk patients with reduced renal function, and a gender comparison sub-analysis, assessing the relative safety and efficacy of ticagrelor in women versus men.
Other data highlights at the ESC Congress 2015 include:
- Data from the APOLLO real-world evidence study, exploring the impact of associated risk factors (such as age ≥65 years, diabetes, history of >1 prior myocardial infarction or renal disease) on the likelihood of recurrent cardiovascular events [abstract P2467], as well as long-term national healthcare costs post-heart attack [abstract 3662], will be featured as poster presentations on Sunday 30 August and Monday 31 August.
- Data from the ATLANTIC-H24 analysis, exploring the effect of pre-hospital versus
in-hospital administration of ticagrelor during the first 24 hours post-procedure, specifically among patients who underwent percutaneous coronary intervention (PCI), will feature on Monday 31 August, as part of the Clinical Trial Update II - Antiplatelet therapy session [abstract 3914].
- Two additional sub-analyses from ATLANTIC, exploring the study results according to gender [abstract P551] and within the French sub-population [abstract P556] will also be featured as poster presentations.
- Data from the SUPPORT study demonstrating the impact of a new interactive smartphone application on improving patient adherence and quality of life [abstract 6649] will be explored during a rapid fire abstract session on Wednesday 2 September.
- A VOYAGER meta-analysis examining the role of statin therapy, such as CRESTOR® (rosuvastatin) [poster P6465], in risk of atherosclerotic cardiovascular disease over a 10 year period will be presented in a poster session on Tuesday 1 September.
ASTRAZENECA ABSTRACTS TO BE FEATURED AT THE ESC CONGRESS 2015
|Abstract #, Title and Author||Time (BST) / Session|
|Abstract P551Worse short-term outcome for women with STEMI. Insights from the ATLANTIC studySwahn E, et al||Saturday 29 August11:00 – 16:00Poster session 1: Infarction acute phase STEMI II|
|Abstract P556Pre-hospital ticagrelor in ST-segment elevation myocardial infarction: the French subgroup analysis of the ATLANTIC studyCayla G, et al||Saturday 29 August11:00 – 16:00Poster session 1: Infarction acute phase STEMI III|
|Abstract P1115Dual anti-thrombotic effects of ticagrelor on Arterial Thrombosis: an anti-platelet agent with anti-coagulant propertiesReiner MF, et al||Sunday 30 AugustModerated poster presentation 10:34 – 10:42Session: Clinical impact and modulation of endothelial (dys)function|
|Abstract P2463High event rate in patients with acute coronary syndromes and atrial fibrillation: Results from the prospective EPICOR RegistryZeymer U, et al||Sunday 30 August14:00 – 18:00Poster session 3: STEMI I|
|Abstract 3032Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: Insights from the PEGASUS-TIMI 54 trialMagnani G, et al||Monday 31 AugustOral presentation 09:24 – 09:41Session: Antithrombotic drugs - An ongoing research|
|Abstract P3317The efficacy and safety of ticagrelor in women versus men with a prior myocardial infarction: Insights from the PEGASUS-TIMI 54 trialO’Donoghue M, et al||Monday 31 August10:00 – 11:00Best posters session 4|
|Abstract P3318Ticagrelor 60 mg twice-daily provides effective platelet inhibition in patients with prior myocardial infarction – the PEGASUS-TIMI 54 platelet function substudyStorey R, et al||Monday 31 August10:00 – 11:00Best posters session 4|
|Abstract 3914Effect of pre-hospital ticagrelor in STEMI patients in the first 24 hours after primary PCI: The ATLANTIC-H24 analysisMontalescot G, et al||Monday 31 August Rapid fire abstract 14:15 – 14:30Session: Clinical Trial Update II - Antiplatelet therapy|
|Abstract 3918Ischemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawalBonaca MP, et al||Monday 31 AugustOral presentation 15:15 – 15:30Session: Clinical Trial Update II - Antiplatelet therapy|
|Abstract P172Biomarker-based prediction model for recurrent ischemic events in revascularized patients with acute coronary syndromesLindholm D, et al||Saturday 29 August Moderated poster presentation 12:38 – 12:47 Session: Post infarction period|
|Abstract P2467Cardiovascular risk in post-myocardial infarction patients: Nationwide real-world data on distribution and impact of combination of risk factors in a real-life settingJernberg T, et al||Sunday 30 August14:00 – 18:00Poster session 3: STEMI I|
|Abstract 3662Long-term healthcare costs after myocardial infarction in a clinical practice setting in Sweden; results from a contemporary nationwide registry studyJanzon M, et al||Monday 31 August08:30 – 12:30Poster session 4: Improvement of medical care in cardiovascular patients: social and economic issues|
|Abstract 3030Effect of Time to interventional treatment on NSTE-ACS Outcomes in PLATOPollack C, et al||Monday 31 AugustOral presentation 08:50 – 09:07Session: Antithrombotic drugs - An ongoing research|
|Abstract 3031Treatment and long-term results of acute coronary syndrome (ACS) in patients on chronic oral anticoagulants (OAC): data from the EPICOR (NCT01171404) studyStepinska J, et al||Monday 31 August Oral presentation 09:07 – 09:24Session: Antithrombotic drugs - An ongoing research|
|Abstract P3319Differences in dual antiplatelet treatment for acute coronary syndrome patients undergoing PCI or not: a Danish nationwide population-based cohort studyGislason G, et al||Monday 31 August10:00 – 11:00 Best posters session 4|
|Abstract P5340Prognostic value of elevated high-sensitivity cardiac troponin T levels in patients with stable coronary artery diseaseBiener M, et al||Tuesday 1 September 08:30 – 12:30Poster session 6: Coronary artery disease and comorbidities I|
|Abstract 4972Treatment pattern of dual antiplatelet therapy in 104,012 patients with acute coronary syndrome; a Swedish nationwide population based cohort studyAngeras O, et al||Tuesday 1 SeptemberRapid fire abstract 08:39 – 08:48Session: Flash news on antithrombotics|
|Abstract 4975Balancing the risk of ischaemic and bleeding events in ACSDucrocq G, et al||Tuesday 1 SeptemberRapid fire abstract 08:57 – 09:06Session: Flash news on antithrombotics|
|Abstract 6649Effects of interactive patient support with a smartphone app on drug adherence and lifestyle changes in myocardial infarction patientsVarenhorst C, et al||Wednesday 2 SeptemberRapid fire abstract 08:57 – 09:06Session: Cardiovascular prevention: what works for whom?|
|Abstract 6654Health outcomes and platelet-aggregation inhibition after acute myocardial infarction in clinical practice. Findings from the PIPER studyEsposti LD, et al||Wednesday 2 SeptemberRapid fire abstract 09:42 – 09:51Session: Cardiovascular prevention: what works for whom?|
|Abstract P6465Estimating the reduction in 10-year atherosclerotic cardiovascular disease risk with statin therapy: a VOYAGER meta-analysisKarlson B, et al||Tuesday 1 September 14:00 – 18:00Poster session 7: Surveillance of risk factors and interventions|
|Abstract P6551YKL-40 in chronic heart failure: Analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA)Kanwal AF, et al||Tuesday 1 September 14:00 – 18:00Poster session 7: Prognosis II|
– ENDS –
NOTES TO EDITORS
1 Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791-800.
BRILINTA is a direct-acting, selective and reversibly binding P2Y12 receptor antagonist in a chemical class called cyclo-pentyl-triazolo-pyrimidines (CPTPs). BRILINTA works by inhibiting platelet activation.
BRILINTA (90mg) is indicated to reduce the rate of thrombotic cardiovascular (CV) events in patients with ACS (unstable angina [UA], non–ST-elevation myocardial infarction [NSTEMI], or ST-elevation myocardial infarction [STEMI]). BRILINTA has been shown to reduce the rate of a combined end point of CV death, MI, or stroke compared to clopidogrel. The difference between treatments was driven by CV death and MI with no difference in stroke. In patients treated with percutaneous coronary intervention, it also reduces the rate of stent thrombosis.
BRILINTA is a registered trademark of the AstraZeneca group.
About the PEGASUS TIMI-54 study
PEGASUS-TIMI 54 (PrEvention with TicaGrelor of SecondAry Thrombotic Events in High-RiSk Patients with Prior AcUte Coronary Syndrome – Thrombolysis In Myocardial Infarction Study Group)is one of AstraZeneca’s largest ever outcomes trials with more than 21,000 patients from over 1,100 sites in 31 countries in Europe, the Americas, Africa andAustralia/Asia. It was conducted in collaboration with the Thrombolysis in Myocardial Infarction (TIMI) Study Group from Brigham and Women’s Hospital (Boston, MA, USA).
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
|Esra Erkal-Paler||UK/Global||+44 20 7604 8030|
|Vanessa Rhodes||UK/Global||+44 20 7604 8037|
|Ayesha Bharmal||UK/Global||+44 20 7604 8034|
|Jacob Lund||Sweden||+46 8 553 260 20|
|Michele Meixell||US||+1 302 885 2677|
|Thomas Kudsk Larsen||+44 20 76048199||+44 7818 524185|
|Eugenia Litz||RIA||+44 20 7604 8233||+44 7884 735627|
|Nick Stone||CVMD||+44 20 76048236||+44 7717 618834|
|Karl Hård||Oncology||+44 20 7604 8123||+44 7789 654364|
|Craig Marks||ING||+44 20 7604 8591||+44 7881 615764|
|Christer Gruvris||+44 20 7604 8126||+44 7827 836825|
|Dial / Toll-Free||+1 301 398 3251||+1 866 381 7277|
Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease,
ING - Infection, Neuroscience and Gastrointestinal
AstraZeneca är ett globalt, innovativt bioläkemedelsföretag med fokus på forskning, utveckling och marknadsföring av receptbelagda läkemedel, primärt för behandling av sjukdomar inom områdena hjärta/kärl, metabolism, andningsvägar, inflammation, autoimmunitet, cancer, infektion och neurovetenskap. AstraZeneca är verksamt i över 100 länder och våra innovativa läkemedel används av miljontals patienter världen över.